GSK advances mRNA flu shot after Phase II immune response results
GSK said its mRNA flu shot candidate generated higher immune responses across all tested strains than standard-dose and high-dose inactivated flu vaccines in younger and older adults. The Phase III study is due to begin in September.
GSK said the candidate generated higher immune responses across all tested strains than both standard—dose and high—dose inactivated flu vaccines in younger and older adults, and was generally well tolerated.The Phase III study, due to begin in September, will be the first late—stage trial of an mR…